These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 19216065)

  • 1. Targeting the EGFR and the PKB pathway in cancer.
    Klein S; Levitzki A
    Curr Opin Cell Biol; 2009 Apr; 21(2):185-93. PubMed ID: 19216065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations and response to epidermal growth factor receptor inhibitors.
    Laurent-Puig P; Lievre A; Blons H
    Clin Cancer Res; 2009 Feb; 15(4):1133-9. PubMed ID: 19228718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
    McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
    J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
    Bianco R; Troiani T; Tortora G; Ciardiello F
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational bases for the development of EGFR inhibitors for cancer treatment.
    Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
    Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer.
    Schiffer HH; Reding EC; Fuhs SR; Lu Q; Piu F; Wong S; Littler PL; Weiner DM; Keefe W; Tan PK; Nash NR; Knapp AE; Olsson R; Brann MR
    Mol Pharmacol; 2007 Feb; 71(2):508-18. PubMed ID: 16968809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S; Grandis JR
    J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
    Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
    Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells.
    Lee DH; Szczepanski MJ; Lee YJ
    J Cell Biochem; 2009 Apr; 106(6):1113-22. PubMed ID: 19229860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
    Garcia-Echeverria C; Sellers WR
    Oncogene; 2008 Sep; 27(41):5511-26. PubMed ID: 18794885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ErbB receptors and signaling pathways in cancer.
    Hynes NE; MacDonald G
    Curr Opin Cell Biol; 2009 Apr; 21(2):177-84. PubMed ID: 19208461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mevastatin-induced neurite outgrowth of neuroblastoma cells via activation of EGFR.
    Evangelopoulos ME; Weis J; Krüttgen A
    J Neurosci Res; 2009 Jul; 87(9):2138-44. PubMed ID: 19224573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease-activated receptor-2 stimulates intestinal epithelial chloride transport through activation of PLC and selective PKC isoforms.
    van der Merwe JQ; Moreau F; MacNaughton WK
    Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1258-66. PubMed ID: 19359428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
    Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
    Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.